Vivimed Labs Limited (NSE:VIVIMEDLAB)
India · Delayed Price · Currency is INR 5.07
-0.07 (-1.36%)
Jul 31, 2026, 3:29 PM IST
Vivimed Labs Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 699.89 | 1,163 | 1,491 | 1,871 | 2,373 |
Other Revenue | 63.19 | 43.71 | 99.76 | 9.68 | 12.7 |
| 763.08 | 1,206 | 1,590 | 1,881 | 2,386 | |
Revenue Growth | -36.75% | -24.15% | -15.43% | -21.16% | -72.62% |
Cost of Revenue | 737.47 | 616.19 | 722.71 | 2,746 | 1,557 |
Gross Profit | 25.61 | 590.21 | 867.76 | -864.86 | 828.14 |
Selling, General & Admin | 249.66 | 288.15 | 361.63 | 350.65 | 386.21 |
Other Operating Expenses | 1,237 | 388.32 | 724.79 | 643.72 | 509.83 |
Operating Expenses | 1,747 | 878.71 | 1,286 | 1,186 | 1,079 |
Operating Income | -1,722 | -288.5 | -418.07 | -2,051 | -250.73 |
Interest Expense | -41.7 | -17.35 | -12.13 | -350.04 | -385.42 |
Currency Exchange Gain (Loss) | - | -0.51 | -13.34 | -0.07 | - |
Other Non Operating Income (Expenses) | - | -12.12 | -14.69 | -8.99 | -12.18 |
EBT Excluding Unusual Items | -1,763 | -318.48 | -458.23 | -2,410 | -648.33 |
Gain (Loss) on Sale of Assets | - | - | - | -4.13 | - |
Asset Writedown | - | - | - | -892.8 | - |
Pretax Income | -1,763 | -318.48 | -458.23 | -3,307 | -648.33 |
Income Tax Expense | 1.37 | 1.13 | -3.77 | -21.17 | 28.17 |
Earnings From Continuing Operations | -1,765 | -319.61 | -454.46 | -3,285 | -676.5 |
Net Income | -1,765 | -319.61 | -454.46 | -3,285 | -676.5 |
Net Income to Common | -1,765 | -319.61 | -454.46 | -3,285 | -676.5 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 83 | 83 | 83 | 83 | 83 |
Shares Outstanding (Diluted) | 83 | 83 | 83 | 83 | 83 |
Shares Change | 0.63% | - | - | - | - |
EPS (Basic) | -21.15 | -3.85 | -5.48 | -39.62 | -8.16 |
EPS (Diluted) | -21.15 | -3.85 | -5.48 | -39.62 | -8.16 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 67.56 | -62.82 | -260.3 | 303.54 | 111.3 |
Free Cash Flow Per Share | 0.81 | -0.76 | -3.14 | 3.66 | 1.34 |
Gross Margin | 3.36% | 48.92% | 54.56% | -45.99% | 34.72% |
Operating Margin | -225.62% | -23.91% | -26.29% | -109.03% | -10.51% |
Profit Margin | -231.26% | -26.49% | -28.57% | -174.69% | -28.36% |
Free Cash Flow Margin | 8.85% | -5.21% | -16.37% | 16.14% | 4.67% |
EBITDA | -1,461 | -86.26 | -218.66 | -1,859 | -67.91 |
EBITDA Margin | -191.48% | -7.15% | -13.75% | -98.86% | -2.85% |
D&A For EBITDA | 260.52 | 202.24 | 199.41 | 191.27 | 182.82 |
EBIT | -1,722 | -288.5 | -418.07 | -2,051 | -250.73 |
EBIT Margin | -225.62% | -23.91% | -26.29% | -109.03% | -10.51% |
Revenue as Reported | 763.08 | 1,206 | 1,590 | 1,881 | 2,386 |